Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AP5346

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2009
Review
2009
ProLindac (AP5346) is DACH (diaminocyclohexane) platinum polymer prodrug currently in phase II clinical development. It uses a 25… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2007
2007
C105 Background: AP5346 comprises a novel hydrophilic biocompatible copolymer which acts as a macromolecular carrier, combined… Expand
Is this relevant?
2006
2006
PURPOSE AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa… Expand
Is this relevant?
2006
2006
AP5346 is a low molecular weight polymer-conjugated platinum antineoplastic agent. The lyophilized drug product has completed a… Expand
Is this relevant?
2006
2006
PurposeTo determine the maximum tolerated dose (MTD) safety and pharmacokinetics of AP5346, a copolymer-linked 1,2… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2006
2006
Syntheses of the novel polymer-bound platinum-based chemotherapeutic agent poly(HPMA)-GGG-Ama=Pt=(1R,2R)-DACH, AP5346, and its… Expand
Is this relevant?